Literature DB >> 6378235

Chronic effects of metoprolol and methyldopa on calf blood flow in intermittent claudication.

M Lepäntalo.   

Abstract

In a placebo-controlled double-blind study 14 hypertensive patients with intermittent claudication were treated with metoprolol (100-200 mg daily) and methyldopa (500-1000 mg daily) for 3 weeks and their effects on heart rate, blood pressure as well as on resting and hyperaemic calf blood flow and vascular resistance were compared. In their antihypertensive effect metoprolol and methyldopa did not differ significantly. In 23 diseased limbs the calf blood flow and vascular resistance remained unchanged at rest during the trial. The active drugs reduced hyperaemic flow (P less than 0.05). The peak flow was reduced by 20% (P greater than 0.01) with metoprolol and by 15% with methyldopa below the initial level and by 17% and by 12% below the level recorded on placebo, respectively. Neither of the drugs influenced vascular resistance during reactive hyperaemia. Thus, in patients with intermittent claudication antihypertensives should be used with care.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6378235      PMCID: PMC1463567          DOI: 10.1111/j.1365-2125.1984.tb05027.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  Intermittent claudication complicating beta-blockade.

Authors:  J C Rodger; C D Sheldon; R A Lerski; W R Livingstone
Journal:  Br Med J       Date:  1976-05-08

Review 2.  Circulatory adjustments to dynamic exercise and effect of physical training in normal subjects and in patients with coronary artery disease.

Authors:  J P Clausen
Journal:  Prog Cardiovasc Dis       Date:  1976 May-Jun       Impact factor: 8.194

3.  Hemodynamics of arterial stenoses at elevated flow rates.

Authors:  D F Young; N R Cholvin; R L Kirkeeide; A C Roth
Journal:  Circ Res       Date:  1977-07       Impact factor: 17.367

4.  Beta adrenergic blockade in hypertension. Practical and theoretical implications of long-term hemodynamic variations.

Authors:  R C Tarazi; H P Dustan
Journal:  Am J Cardiol       Date:  1972-05       Impact factor: 2.778

5.  Suppression of Raynaud's phenomenon by methyldopa.

Authors:  D P Varadi; A M Lawrence
Journal:  Arch Intern Med       Date:  1969-07

6.  Effect of blood pressure reduction on tissue perfusion.

Authors:  R Sivertsson
Journal:  Acta Med Scand Suppl       Date:  1979

7.  Peripheral vasospasm during beta-receptor blockade - a comparison between metoprolol and pindolol.

Authors:  K Eliasson; L E Lins; K Sundqvist
Journal:  Acta Med Scand Suppl       Date:  1982

8.  Effect of beta-blocking drugs on peripheral blood flow in intermittent claudication.

Authors:  R S Smith; D J Warren
Journal:  J Cardiovasc Pharmacol       Date:  1982 Jan-Feb       Impact factor: 3.105

9.  Effect of long-term beta-adrenergic-blockade on calf blood flow in hypertensive patients.

Authors:  M Lepäntalo; K J Tötterman
Journal:  Clin Physiol       Date:  1983-02

10.  Are selective beta-adrenoceptor blocking drugs an advantage?

Authors:  M J Kendall
Journal:  J R Coll Physicians Lond       Date:  1981-01
View more
  9 in total

Review 1.  Adverse reactions and interactions with beta-adrenoceptor blocking drugs.

Authors:  R V Lewis; D G McDevitt
Journal:  Med Toxicol       Date:  1986 Sep-Oct

2.  Haemodynamic effects of atenolol, labetalol, pindolol and captopril: a comparison in hypertensive patients with special reference to changes in limb blood flow, heart rate and left ventricular function.

Authors:  D H Roberts; Y Tsao; S F Grimmer; P A Winstanley; M L Orme; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1987-08       Impact factor: 4.335

Review 3.  Methyldopa for primary hypertension.

Authors:  Greg T Mah; Aaron M Tejani; Vijaya M Musini
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

Review 4.  Adverse reactions with beta-adrenoceptor blocking drugs. An update.

Authors:  R V Lewis; C Lofthouse
Journal:  Drug Saf       Date:  1993-10       Impact factor: 5.606

5.  beta blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination.

Authors:  S A Solomon; L E Ramsay; W W Yeo; L Parnell; W Morris-Jones
Journal:  BMJ       Date:  1991-11-02

6.  Impact of betablockers on general and local outcome in patients hospitalized for lower extremity peripheral artery disease: The COPART Registry.

Authors:  Tristan Mirault; Alexandre Galloula; Jean-Pierre Cambou; Philippe Lacroix; Victor Aboyans; Carine Boulon; Joel Constans; Alessandra Bura-Riviere; Emmanuel Messas
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

Review 7.  Outcomes of Lower Extremity Endovascular Revascularization: Potential Predictors and Prevention Strategies.

Authors:  Federico Biscetti; Elisabetta Nardella; Maria Margherita Rando; Andrea Leonardo Cecchini; Antonio Gasbarrini; Massimo Massetti; Andrea Flex
Journal:  Int J Mol Sci       Date:  2021-02-18       Impact factor: 5.923

Review 8.  Beta blockers for peripheral arterial disease.

Authors:  Sharath Chandra Vikram Paravastu; Derick A Mendonca; Anthony Da Silva
Journal:  Cochrane Database Syst Rev       Date:  2013-09-11

9.  Effect of blood pressure lowering medications on leg ischemia in peripheral artery disease patients: A meta-analysis of randomised controlled trials.

Authors:  Diana Thomas Manapurathe; Smriti Murali Krishna; Brittany Dewdney; Joseph Vaughan Moxon; Erik Biros; Jonathan Golledge
Journal:  PLoS One       Date:  2017-06-02       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.